Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad
This strategic investment strengthens Cohance's integrated oligonucleotide platform
This strategic investment strengthens Cohance's integrated oligonucleotide platform
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The site’s GMP Certification has been successfully renewed
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Subscribe To Our Newsletter & Stay Updated